Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

NCT00769145 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Corneal Neovascularization

Interventions

DRUG: Ranibizumab

Sponsor

University of Miami

Collaborators

[object Object]